Although GLP-1 receptor agonists effectively manage weight and glycemic control in overweight/obese patients, their association with increased cancer risk warrants cautious application, especially in individuals with a predisposition to thyroid or pancreatic cancers. The gene discussed is GLP1R; the disease is familial pancreatic carcinoma.